

Jonathan Sheffield  
CEO NIHR CRN




# What's new and how we respond

- Environment- NHS and Research
- Technology- Opportunities
- Future Network direction


# EU total clinical trials: all phases

Data source: MHRA




# UK v EU new trials by year

## All Phases




# Number of CTA 2006-2012 All Phases

## Non-Commercial vs Commercial



Data demonstrates a sustained increase in the number of Commercial Phase 2-4 studies since 2011

Data demonstrates a decline in the number of Non-Commercial Phase 2-4 studies since 2011




# Number of UK commercial trial applications received

Source MHRA




National Institute for  
Health Research

Clinical Research Network




# UK v the world

- Patient enrolment per year, by country as a percentage of the Global Total.



Data source: Anonymous CRO - there is no single source for patient recruitment data, however, this graph shows where **one leading CRO** is choosing to put their studies

# Number of Studies on NIHR CRN Portfolio




*n = Number of Studies*

Initialised = study record entered onto the portfolio database, not study open for recruitment



# Number of participants recruited into studies



*n = Number of participants*

# Percentage of NIHR CRN Portfolio Commercial studies Delivering to Time and Target


Clinical Research Network



25% increase on performance in 2012/13

*n = Number of studies recruiting to time and target*


# Median Calendar Days Taken to Obtain NHS Permission



*This is the median of total time to obtain study-wide approval and the time taken to obtain local NHS permission at each site for each study*

*n = Number of Studies*


# Percentage of Commercial NIHR CRN Portfolio Studies Achieving First Participant within 30 Days of NHS Permission/FNSIV



*n = Number of studies achieving first participant within 30 days*

# NHS Engagement with Industry

**Fig 20: Percentage of NHS Trusts participating in commercial contract studies**




# NIHR CRN SERVICE OFFERINGS TO INDUSTRY

# Disruptive Innovation.....

- New web based feasibility service launched in May 2013
- Offers 3 key services developed in conjunction with Industry
- Provides complimentary value add intelligence to boost company feasibility
- Utilises wealth of CRN experience and past performance data
- Improves predictability of delivery
- Joint **evidence based** target setting


# Feasibility services

## NIHR CRN commercial feasibility services






# Number of IAG Service Requests / Month




**Equates to 1115 unique Study Protocols, 2030 individual service requests to date**

# Number of IAG Service Requests / Month



June applications reached a record high since service launch


# Number of Unique Companies Requesting Feasibility Services



NB Cumulative totals shown each month

- Effective and regular communication
- Timely escalation of issues
- Clear and mutually agreed targets
- Equal responsibility for training and dissemination of best practice among teams
- Commitment to joint performance management

*Readiness to do things differently*



# Proof of the Partnership

- 35 global first patients in 2013/14 demonstrates global competitiveness
- *“This is all about partnership with NIHR and local research Network colleagues and team work, working better together nationally which will continue our success in a difficult marketplace. Fast start up can only lead to more trials placed in the UK, better patient outcomes and experience of new medicines.”*

# Helping you to get the best out of us

## Network Experts

We want companies and Contract Research Organisations to fully understand the nature of the support we provide, and how to access it.

So far we've trained **68** Network Experts from **45** companies to act as in-house advisors




# Shaping the Future

- Evolve to remain smart and respond to changing landscape
- A critical aspect of achieving improved performance relied on the CRN doing things differently –with great results
- Quality- high performing research teams
- Going Global- Business Development-Championing the NIHR and the NHS

***Networking Locally, Delivering Globally***

# The new NHS Constitution for England

- A commitment to promote, conduct and use research to improve the current and future health and care of the population is enshrined in NHS England's seven key principles
- New pledge to use anonymised information to support research and improve care for others
- A commitment to inform patients of research studies in which they may be eligible to participate





# Patients and Public

- Engagement at all levels of research
- NETSCC- developing in areas of NHS priority
- Charity and Industry focus
- Delivery
- Transparency of results

# New Technology


- Personalised medicines
- Adaptive trial designs
- Big data
- Crowd sourcing
- Adaptive licensing

# Future: personalized/genomic medicine

- **Stratified medicines:**


- Intensive genotyping and phenotyping
- Larger number of smaller studies: multi-centre and specialist in nature
- Fewer patients required – but harder to find; use of technology for feasibility becomes key
- Current “individual” Trust approval model may be unsustainable where only a few patients will be recruited at each centre; reciprocal model of R&D may become essential






- **Big Data** – stitches data sources together: volume, velocity, variety
- Clinical Practice Research Datalink: NIHR supported; will give the UK a unique selling point for researchers
- Clinical Research Network: linking Portfolio with NHS datasets to assist study feasibility
- CRN open data platform: dashboard tools to make our data more useful – available from summer

# BIG data



**CPRD**  
MORE DIMENSIONS TO DATA



# “Real world” studies



**Please note:**

The Salford Lung Study is only available to patients who are residents of the City of Salford in the UK.

[Report a Suspected Side Effect](#)

## The Salford Lung Study.

*Researching treatment of chronic obstructive pulmonary disease and asthma in Salford.*

### If you have COPD

(chronic obstructive pulmonary disease, also known as chronic bronchitis or emphysema)

**Please Click Here** →


### If you have asthma

**Please Click Here** →



© 2012 GlaxoSmithKline group of companies. All rights reserved. GlaxoSmithKline UK Limited:  
Registered in England & Wales No 4310159 Registered office 980 Great West Road, Brentford, Middlesex TW8 9GS.  
This site is for UK residents only | [Terms of use](#) | [Privacy policy](#) | [Cookie notice](#)  
RECE/FFT/0032/12/ 10 May 2012

# Role of www in patient recruitment



- Highly-sophisticated online patient recruitment, self-monitoring and support systems now in place
- Role of social media in driving patients to study sites
- UK Clinical Trials Gateway developing in that direction
- Customer route to research may be different in the future: patients take initiative

# Aims for the future

- Over the next year:
  - Deliver CPMS and LPMS
  - Continue performance improvement
  - Further Improve commercial performance
- Over the next 5 years
  - Standardise
  - Modernise and adapt
  - Embrace new technology

# Conclusion

- Network has changed and adapted
- Great opportunities but we will have to continue to change
- We need to develop an offering which is clear to all our stakeholders



It is about patients

The new  
treatment has  
given me hope.  
If it is successful,  
it will be better  
than winning the  
lottery.

Network clinical trial  
patient

